La chaîne d'options affiche les données clés des options sur actions de Zymeworks à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Zymeworks..

Zymeworks (NASDAQ:ZYME) Stock, Chaîne d'Options

ZYMEWORKS INC

Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Zymeworks Inc

New BD FACSDiscover&#x2122; A8 Cell Analyzer Brings Leading-Edge Capabilities to Wider Range of Scientists across Academia and Biopharma
FRANKLIN LAKES, N.J., May 13, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>), a leading global medical technology company, announced the global commercial launch of the world's first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, enabling more researchers across a wider range of applications to uncover deeper insights and dynamics from cells once invisible in flow cytometry experiments – with increased ease and throughput.

News

BD Launches FACSDiscover A8 Cell Analyzer, Featuring Spectral And Real-Time Cell Imaging Technologies For Scientists In Academia And Biopharma

Needham analyst Charles Shi reiterates Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Buy and maintains $325 price target.

Price Target

Reiteration

Analyst Ratings

CDNS

Needham Reiterates Buy on Cadence Design Systems, Maintains $325 Price Target

WIIM

COIN

Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective before the opening of trading on Monday, May 19.

Sea shares are trading higher after the company reported better-than-expected Q1 EPS results.

On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) FY2025 Revenue expected to be at least CHF 2.86 billion.

Guidance

ONON

On Holding FY2025  Revenue expected to be at least CHF 2.86 billion.

Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. This is a 81.08 percent increase over losses of $(0.74) per share from the same period last year.

Earnings

Earnings Beats

CLRB

Cellectar Biosciences Q1 EPS $(0.14) Beats $(0.16) Estimate, Cash $13.9M

Biotech

General

SKYE

Skye Bioscience Presented A Clinical Model On Peripheral CB1 Inhibition For Weight Loss At European Congress On Obesity

Rogers Sugar (TSX:<a class="ticker" href="https://www.benzinga.com/stock/RSI#TSX">RSI</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.15 by 13.33 percent. This is a 23.53 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $326.31 million which beat the analyst consensus estimate of $323.43 million by 0.89 percent. This is a 8.43 percent increase over sales of $300.94 million the same period last year.

Earnings Misses

TSX:RSI

Rogers Sugar Q2 Adj. EPS $0.13 Misses $0.15 Estimate, Sales $326.31M Beat $323.43M Estimate

CODA

Coda Octopus Secures $1.5M US Navy Order For DAVD Tethered Systems With Echoscope, Highlighting Continued Investment in Subsea Tech

Latest MES release helps pharmaceutical and biopharmaceutical manufacturers simplify system management, improve flexibility and speed time-to-value
MILWAUKEE, May 13, 2025 /PRNewswire/ --&nbsp;<a href="https://www.rockwellautomation.com/">Rockwell Automation, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>), the world's largest company dedicated to industrial automation and digital transformation, today announced the launch of <a href="https://www.rockwellautomation.com/en-us/products/software/factorytalk/operationsuite/mes/life-sciences.html">FactoryTalk&#xAE; PharmaSuite&#xAE; 12.00</a>. The latest release of its manufacturing execution system (MES) is designed to support the unique needs of regulated pharmaceutical and biopharmaceutical manufacturing environments, helping companies simplify system management, accelerate deployments and scale production more efficiently.

Rockwell Automation Launches FactoryTalk PharmaSuite 12.00 To Simplify System Management, Accelerate Deployments And Scale Production More Efficiently

Toyota continues to move its electrified vehicle portfolio forward by announcing its 2026 bZ Battery Electric Vehicle (BEV). For model year 2026, the model makes advancements in range, output, charging performance, and vehicle design. Leading the charge is a larger lithium-ion battery with a higher total capacity of up to 74.7-kWh, equipped on a newly available XLE Front-Wheel-Drive Plus (FWD Plus) model, as well as the XLE All-Wheel-Drive (AWD) and Limited (FWD/AWD) grades. Models equipped with the new battery are projected to have a manufacturer-estimated rating of&nbsp;up to 314 miles&#x2A; of range on a full charge. A 57.7-kWh battery will also be available on a XLE FWD model.
&nbsp;
The 2026 bZ will be equipped with a North American Charging System (NACS) charging port, giving it access to thousands of high-speed charging stations nationwide. Under ideal conditions when using DC fast charging&#x2A; it is capable of charging from 10% to-80% battery capacity in around 30 minutes. The 2026 Toyota bZ also adopts <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4425982-1&amp;h=1118701590&amp;u=https%3A%2F%2Fdriveelectric.gov%2Fnews%2Funiversal-plug-and-charge&amp;a=Plug+%26+Charge">Plug &amp; Charge</a>&nbsp;capability, an industry standard protocol that allows automatic identification, authentication and authorization at selected charging networks, reducing the need for multiple mobile charging applications.
Toyota's compact, lightweight and energy-efficient eAxles have also been upgraded. They now use silicon carbide (SIC) semiconductors, which help deliver higher power output. For AWD models, output increases by 50% to 338 combined system net horsepower (hp), making it capable of going from 0-60 MPH in 4.9 seconds on AWD models. Front Wheel Drive models also boost their output, now delivering up-to 221 hp (previously 201 hp). For AWD models, output increases by 50% to 338 combined system net horsepower (hp), making it capable of going from 0-60 MPH in around 5 seconds. Front Wheel Drive models also boost their output, now delivering up-to 221 hp (previously 201 hp).
The model also receives a name change, switching from the Toyota bZ4X to the Toyota bZ, simplifying the name for customers. The 2026 bZ also presents a refreshed exterior design that harmoniously blends form and function. While maintaining its distinctive aesthetic, the updated model incorporates subtle refinements to the front fascia and lighting elements, with slim LED daytime running lights that integrate into a sleek hammerhead front end. Redesigned front overfenders also change the look, with a newly available color-matched moulding that blends into a lower profile front fascia.

Toyota Unveils 2026 bZ EV With 314-Mile Range, Faster Charging, and Sleek New Look

Under the terms of the agreement, $15 million will be drawn at closing. An additional $25 million is available in 2025 at Altimmune's option, subject to certain clinical and financial milestones. The remaining $60 million is available beginning in 2026, with $15 million subject to the achievement of certain clinical and financial milestones and up to $45 million available subject to the approval of Hercules. The facility is structured as interest only for the first 24 months, extendable up to 42 months on achievement of milestones. The loan matures 48 months from closing, and no warrants are included in the agreement.
 &nbsp;

Financing

Altimmune Secures Up To $100M In Credit Facility From Hercules Capital

SLAB

Silicon Laboratories Sees Q2 Adj EPS $(0.01)-$0.19 vs $(0.09) Est; Sees Sales $185.000M-$200.000M vs $177.49M Est

CRWV

CoreWeave Partners With MERLIN To Launch NVIDIA Hopper Supercomputer In Barcelona, Hosts 10,224 H200 GPUs At New 15MW Green Data Center With Plans For Blackwell Expansion by 2026

It's full steam ahead through Panama for Shake Shack! Shake Shack Inc. ("Shake Shack" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) has partnered with Grupo Attie-Multifood Enterprises to bring the iconic brand to Panama. As part of the deal, the partnership plans to open 12 Shacks across the Panamanian market by 2035, with its first Shack scheduled to open in 2026 - marking an exciting new chapter in the Company's international journey.
Shake Shack is proud to partner with Grupo Attie-Multifood Enterprises, a powerhouse Panamanian conglomerate with operations across Panama, Colombia, Chile, and Mexico. They currently operate over 200 in-stores and 200 stores in Latin America, and specialize in real estate, food and beverage, retail, finance, and online entertainment and gaming.

SHAK

Shake Shack Heads to Panama in New Deal, Plans 12 Locations by 2035

LITM

Snow Lake Resources Announces C$1.1M Investment In Commerce Resources Corp's C$2.2M Convertible Note Financing

Funding to provide capital to stage-gate to the next stage of FEED engineering with an update to the technical report on track in the near term
5E plans to issue 1,789,779 shares of common stock at $3.55 per share
HESPERIA, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / May 13, 2025 / 5E Advanced Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEAM#NASDAQ">FEAM</a>)(ASX:5EA) ("5E" or the "Company"), a boron and lithium company with U.S. government Critical Infrastructure designation for its 5E Boron Americas Complex, today announced it has entered into a securities purchase agreement to issue and sell 1,789,779 shares of common stock at a price of $3.55 per share in a private placement. The transaction is expected to close on May 15, 2025, subject to satisfaction of customary closing conditions. The Company remains on track to issue an update to its technical report summary in the near term and expects the funding from this equity issuance to provide the capital to stage-gate to the next phase of commercial engineering design, after the publishing of the Company's anticipated technical report update.

FEAM

5E Advanced Materials Enters Into Securities Purchase Agreement To Issue And Sell 1,789,779 Shares At $3.55/Shr In Private Placement

On Monday, May 12, U.S. markets closed sharply higher after the U.S. and China agreed to a 90-day temporary tariff reduction, easing trade tensions that had escalated since April. The S&amp;P 500 reached its highest level since early March. Investors shifted toward riskier assets, prompting a relief rally, though analysts warned of potential long-term complications.
In economic news, the U.S. government reported a $258 billion budget surplus for April, marking a 23% increase from last year.
Most S&amp;P 500 sectors ended higher on Monday, led by technology, consumer discretionary, and communication services, while utilities declined.
The Dow Jones Industrial Average rose 2.81% to 42,410.10, the S&amp;P 500 gained 3.26% to 5,844.19, and the Nasdaq surged 4.35% to 18,708.34.
Asia Markets Today
<ul class="wp-block-list">
<li>On Tuesday, Japan's Nikkei 225 closed 1.54% higher at 38,224.00, led by gains in the Real Estate, Banking, and Textile sectors.</li>
<li>Australia's S&amp;P/ASX 200 gained 0.43%, ending the session at 8,269.00, led by gains in the IT, Energy, and Healthcare sectors.</li>
<li>India's Nifty 50 was down 1.42% at 24,567.90, and Nifty 500 fell 0.74% to 22,344.45.</li>
<li>China's Shanghai Composite gained 0.17% to 3,374.87, and Shanghai Shenzhen CSI 300 was up 0.15% at 3,896.26.</li>
<li>Hong Kong's Hang Seng closed the session 1.87% lower at 23,108.27.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45368852/trump-lowers-de-minimis-tariff-on-chinese-imports-from-120-to-54-pauses-200-postal-fee-amid-90-day-trade-shift" rel="noreferrer noopener">Trump Lowers De Minimis Tariff On Chinese Imports From 120% To 54%, Pauses $200 Postal Fee Amid 90-Day Trade Shift</a>
Eurozone at 05:45 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.01%.</li>
<li>Germany's DAX index gained 0.02%.</li>
<li>France's CAC 40 rose 0.05%.</li>
<li>The U.K.'s FTSE 100 index traded higher by 0.01%.</li>
</ul>
Commodities at 05:45 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading higher by 0.65% at $62.34/bbl, and Brent was up 0.48% at $65.28/bbl.</li>
<li>Oil prices rose, supported by strong fuel demand, though gains were capped by rising OPEC+ supply and uncertainty over the lasting impact of the U.S.-China trade truce.</li>
<li>Natural Gas gained 0.93% to $3.680.</li>
<li>Gold was trading higher by 0.87% at $3,255.44, Silver was up 1.83% to $33.225, and Copper rose 0.80% to $4.6580.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.16%, S&amp;P 500 futures declined 0.35%, and Nasdaq 100 futures fell 0.43%.
Forex at 05:45 AM ET
<ul class="wp-block-list">
<li>The U.S. Dollar Index declined 0.26% to 101.56, USD/JPY was down 0.36% to 147.90, and USD/AUD fell 0.60% to 1.5600.</li>
<li>The dollar eased slightly on Tuesday but held most of its gains from the previous session, driven by optimism over the U.S.-China tariff truce.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

Markets

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia And Europe Markets Trade Mixed Following US-China Tariff Deal Optimism - Global Markets Today While US Slept

<a href="https://pr.report/acon">Idaho Strategic Resources, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDR#NYSE">IDR</a>) ("IDR" or the "Company") is pleased to announce that the Company has signed a Memorandum of Understanding ("MOU") with <a href="https://pr.report/acoo">Clean Core Thorium Energy, Inc.</a> ("CCTE") to evaluate the feasibility of thorium mining, processing, and other relevant supply chain steps for CCTE's ANEEL fuel - an advanced nuclear fuel comprised of thorium and high assay low-enriched uranium ("HALEU") for use in pressurized heavy water reactors ("PHWRs").
Idaho Strategic and CCTE believe this MOU to be very complimentary to both companies' business plans and allow each to leverage their respective expertise to advance a "Made in America" supply-chain for thorium-based ANEEL fuel. The two companies share the belief that nuclear power is the logical choice to provide 100% carbon-free baseload power, and that CCTE's thorium-based ANEEL fuel raises the bar even higher given the inherent benefits of thorium as a nuclear fuel source.

Idaho Strategic Joins Clean Core to Explore US Thorium Supply Chain for Next-Gen Nuclear Fuel

Management

CGEN

Compugen Announces Eran Ophir, Ph.D. Appointed As CEO And President

Press Releases

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Zymeworks Announces Participation in Upcoming Investor Conferences

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Zymeworks to Report First Quarter 2025 Financial Results and  Host Conference Call on May 8, 2025

Health Care

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Comments

Zymeworks

Zymeworks (ZYME) Options

Zymeworks (NASDAQ:ZYME) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL